

Demuth et al.
09/745,883
IDS
Page 1 of 6



RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.	SERIAL NO.
	20784/5	09/745,883
	APPLICANT(S): Demuth et al.	
FILING DATE: December 21, 2000	ART UNIT: 1653	

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
CMK	AA	2,961,377	11/22/1960	Shapiro et al.	167	65	
	AB	3,174,901	3/23/65	Sterne	167	65	
	AC	3,879,541	4/22/1975	Kabbe et al.	424	326	
CMK	AD	3,960,949	6/1/1976	Ahrens et al.	260	564 B	
	AE	4,028,402	6/7/1977	Fischer et al.	260	501.14	
CMK	AF	4,935,493	6-19-1990	Bachovchin et al	530	331	
	AG	5,462,928	10/31/95	Bachovchin et al.	514	19	
CMK	AH	5,512,549	4-30-1996	Chen et al.	514	12	
	AI	5,543,396	8/6/96	Powers et al.	514	19	
	AJ	5,939,560	8/17/99	Jenkins et al.	548	535	
	AK	6,006,753	12-28-1999	Efendic	128	898	

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

Demuth et al.
09/745,883
IDS
Page 2 of 6



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY DOCKET NO. 20784/5	SERIAL NO. 09/745,883
		APPLICANT(S): Demuth et al.	
		FILING DATE: December 21, 2000	ART UNIT: 1653

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
	BA	WO 01/62266 A2	08/30/01	PCT	A61K	38/00	Y
CMK	BB	WO 00/53171	9/14/00	PCT	A61K	31/155	Y
CMK	BC	DT 25 42 598 A1	4/22/76	Germany	C07C	129/16	N
CMK	BD	FR 2 696 740 A1	4/15/94	France	C07D	207/404	N
CMK	BE	FR 2 085 665	12/31/71	France	A61K	27/00	N
CMK	BF	WO 97/40832	11/6/97	PCT	A61K	31/425	Abstract only
CMK	BG	WO 95/15309	6/8/95	PCT	C07D	207/16	Y
CMK	BH	JP 4334357	11/20/92	JAPAN	C07C	233/57	Abstract only
CMK	BI	WO 95/29691	11/09/95	PCT	A61K	38/00	Y
CMK	BJ	WO 98/22494	5/28/98	PCT	C07K	5/06	Y
	BK	WO 00/01849	01/13/00	PCT	C12Q	1/68	Y
CMK	BL	EP 0 658 568 A1	6/21/95	EPO	C07K	14/605	Y
	BM	DD 296 075 A5	11/21/91	Germany	C07D	295/04	Y
CMK	BN	DD 296 075 A5	11/21/91	Germany	C07D	295/04	N
CMK	BO	EP 0 708 179 A2	4/24/96	EPO	C12N	15/16	Y
	BP	EP 0 995 440 A1	4/26/00	EPO	A61K	31/425	N
	BQ	WO 91/11457	08/8/91	PCT	C07K	7/34	Y
	BR	WO 91/16339	10/31/91	PCT	C07K	5/10	Y
	BS	WO 98/19998	5/14/98	PCT	C07D	207/00	Y
	BT	WO 91/17767	11/28/91	PCT	A61K	37/54	Y

Demuth et al.
09/745,883
IDS
Page 3 of 6



RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 20784/5	SERIAL NO. 09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

FOREIGN PATENT DOCUMENTS

<u> </u>	BU	JP 04-288098	10/13/92	JP	C07K	7/06	(Abstract Only)
---------------	----	--------------	----------	----	------	------	-----------------

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

<i>CMK</i>	CA	Campbell, I.W. New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, "Sulphonylureas and metformin: efficacy and inadequacy". 3:33-51 (1990).
<i>CMK</i>	CB	The Merck Index, 11 th Edition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, Page 934
<u> </u>	CC	The Merck Index, 12 th Edition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, Page 1014.
<i>CMK</i>	CD	Martindale The Extra Pharmacopoeia, 30 th Edition, London Pharmaceutical Press, 1993, Page 1619.
<u> </u>	CE	Martindale The Extra Pharmacopoeia, 30 th Edition, London Pharmaceutical Press, 1993, Page 36.
<i>CMK</i>	CF	CHEMICAL ABSTRACTS, vol. 115. No. 15, 14. October 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN EKKEHARD ET AL: "Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes"
<i>CMK</i>	CG	CHEMICAL ABSTRACTS, vol. 126, no. 2, 13. January 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL A. ET AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides"
<i>CMK</i>	CH	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21. Juni 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Hosoda, et al, "Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors", November 1992 (1992-11-20)
<i>CMK</i>	CI	ARAI ET AL: "Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain" CHEMICAL AND PHARMACEUTICAL BULLETIN., Bd. 41, No. 9, 1993, pages. 1583-1588.
<i>CMK</i>	CJ	AMASHEH, S., et al., "Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes". J. Physiol. 504, 169-174 (1997)
<u> </u>	CK	DURINX, C.; et al.; "Reference Values for Plasma Dipeptidyl-Pepidase IV activity and their Association with Other Laboratory Parameters". Clin Chem Lab Med 2001, February; 39 (2) :155-9, 1 page.
<u> </u>	CL	GOSSRAU, R.; "Cytochemistry of Membrane Proteases". Histochem J, 1985, July; 17 (7) :737-71, 1 page.

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

Demuth et al.
09/745,883
IDS
Page 4 of 6



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.	SERIAL NO.
	20784/5	09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CM	HAHN, T.; et al.; "Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae". <i>Acta Histochem</i> 1993, December, 1995 (2) :185-92, 1 page.
CN	HEYMANN, E.; et al.; "Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation." <i>Klin Wochenschr</i> , 1984, January, 2;62 (1) :2-10, 1 page.
CO	MAGYAR, C.E.; et al.; "Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension." <i>Am J Physiol Renal Physiol</i> , 2000, August; 279 (2) :F358-69, 1 page.
CP	PAPIES, B.; et al.; "Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension." <i>Cor Vasa</i> , 1991; 33 (3) :218-26, 1 page.
CQ	QURESHI, N.U.; et al., "Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock". <i>Regul Pept</i> , 1998, September 25; 75-76:215-20, 1 page.
CR	Index Nominum, International Drug Directory 1992/1993, Medpharm Scientific Publishers, pages 728-729.
CS	The Merck Index, An Encyclopedia of Chemicals and Drugs, 9 th Edition, Merck & Co., Inc., 1976, page 773
CT	C.J. Bailey et al., <u>New Antidiabetic Drugs</u> , Smith-Gordon Nishimura, 1990, p. 36.
CK	CU Hoffmann et al., <u>Journal of Chromatography A</u> , "Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary eletrophoresis", 1995, 716:355-362.
CV	C.B. Welch, <u>Medical Management of Non-Insulin-Dependent (Type II) Diabetes</u> , 3 rd edition, American Diabetes Association, "Diagnosis and Classification" p. 3, 1994, Pharmacologic Intervention (1 page).
CW	Mannucci et al., <u>Diabetes Care</u> , "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects", 24(3): 489-494, March 2001.
CX	Stryer, <u>Biochemistry</u> 3 rd Ed., "Protein Conformation, Dynamics, and Function", 1988, p 191-193.
CY	Pauly et al., <u>Regulatory Peptides</u> , "Abstracts Issue: Abstracts from the 11 th International Symposium on Regulatory Peptides", July 15, 1996, 64(1-3): 148 plus cover.
CZ	Gutniak et al., <u>New England Journal of Medicine</u> , "Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients With Diabetes Mellitus", 1992, 326: 1316-1322.

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

Demuth et al.
09/745,883
IDS
Page 5 of 6



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.	SERIAL NO.
	20784/5	09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CMK	CAA	Hendrick et al., <u>Metabolism – Clinical and Experimental</u> , "Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats", January 1993, 42(1): 1-6.
CMK	CAB	Nauck et al., <u>Diabetologia</u> , "Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients", 1993, 36: 741-744.
CMK	CAC	Gutniak et al., <u>Diabetes Care</u> , "Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM", September 1994, 17(9): 1039-1044.
CMK	CAD	Deacon et al., <u>Journal of Clinical Endocrinology and Metabolism</u> , "Degradation of Glucagon-Like Peptide-1 by Human Plasma In Vitro Yields and N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite In Vivo", 1995, 80(3): 952-957.
	CAE	H.A. Smith et al., <u>Veterinary Pathology</u> (fourth edition), "Diseases and Disorders of Metabolism: Deficiency Diseases", 1972, p 1018-1020.
	CAF	G.G. Duncan, <u>Diseases of Metabolism (Asian edition)</u> , "Diabetes Mellitus", 1966, p 951-957.
	CAG	T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 In Vitro and In Vivo by DP IV", <u>Endocrinology</u> , Vol. 136(8), 1995, p 3585-3596.
	CAH	C.F. Deacon et al., <u>Diabetes</u> , "Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded from the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects", September 1995, 44: 1126-1131.
CMK	CAI	Pauly et al., <u>Metabolism</u> , "Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-Thiazolidide", 1999, 48(3): 385-389.
	CAJ	Vidal, 1993, 69 th Edition, p. 612-613.
	CAK	Goodman & Gilman's <u>The Pharmacological Basis of Therapeutics</u> , Ninth Edition, 1996, p. 1510.
	CAL	Nathan et al., <u>Diabetes Care</u> , "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects", February 1992, 15(2): 270-275.
	CAM	Pschyrembel, <u>Kininisches Wörterbuch</u> 257, Auflage, 1994, 9 pages.
	CAN	Frohman et al., <u>Journal of Clin. Invest.</u> , "Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma In Vitro and in Vivo to a Biologically Inactive Product Cleaved at the NH ₂ Terminus", Volume 78, October 1986, p 906-913

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

Demuth et al.
09/745,883
IDS
Page 6 of 6



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.	SERIAL NO.
	20784/5	09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CAO	Snow et al., <u>Advances In Medicinal Chemistry</u> , "Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents", Vol. 3, 1995, p 149-177.
CHR	Thorens et al., <u>Diabetes</u> , "Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM", 1993, 42:1219-1225.
CAQ	Ashworth et al., <u>BIOORG. MED. CHEM. LETT.</u> , "2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", 1996, 6(10): 1163-1166.
CAR	Endroczi et al., <u>ACTA PHYSIOL. HUNG.</u> , "Dipeptidyl peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and Zn ²⁺ in Vitro", 1990, 75(1): 35-44.
CAS	Lee, H.S. et al., "Cathepsin B Inhibitory Peptides Derived from β -Casein," <u>Peptides</u> 21 (2000) 807-809.
CAT	Edwards, J.V. et al., <u>J. Peptide Res.</u> , "Synthesis and Activity of NH ₂ - and COOH-Terminal Elastase Recognition Sequences on Cotton," 1999, 54: 536-543.

Examiner: *Chir*Date: *11/03*